From Passenger to Driver: How Clonal Hematopoiesis Rewires Cancer Risk | MGR | 8 April 2026

Why It Matters

The discovery of JAK2‑driven clonal hematopoiesis directly yielded a life‑extending therapy, demonstrating how patient‑centered genomic research can fast‑track new standards of care.

Key Takeaways

• Physician‑scientist pivoted from bedside to genomics to tackle AML.
• Large‑scale sequencing identified JAK2 V617F as driver in myeloproliferative neoplasms.
• Collaboration with Insight led to first JAK inhibitor approved for these diseases.
• Early patient samples and open‑access data enabled decades‑long translational research.
• Success illustrates how clinician‑led discovery can accelerate diagnostics and therapies.

Summary

The talk chronicles a physician‑scientist’s transition from treating acute myeloid leukemia patients to uncovering the genetic underpinnings of related myeloproliferative disorders. By leveraging early‑era genomic sequencing on patient‑derived blood and buccal samples, the speaker’s lab identified the JAK2 V617F gain‑of‑function mutation as a pervasive driver in polycythemia vera, essential thrombocythemia, and myelofibrosis.

Key insights include the power of patient‑first observations, the feasibility of large‑scale sequencing before it became routine, and the strategic choice to pursue a fast‑moving field where community discoveries amplify impact. The collaboration with a small Delaware biotech, Insight, turned the genetic finding into a pre‑clinical proof‑of‑concept, culminating in a phase‑III trial that secured regulatory approval for the first JAK inhibitor, now a standard of care that shrinks spleens and improves symptoms.

The speaker highlights a memorable mentor moment: “If you work on a fast‑moving field, you rise with the tide,” underscoring the value of collective progress. He also stresses that his MD background drove a bias toward action—pursuing experiments despite uncertainty—paired with PhD colleagues who questioned feasibility, creating a productive tension.

Implications are clear: clinician‑driven genomics can rapidly translate into therapeutics, reshaping treatment paradigms for clonal hematopoiesis‑related cancers. The story reinforces the importance of open data, cross‑disciplinary collaboration, and sustained investment in translational pipelines to bring bench discoveries to bedside.

Original Description

This Stanford Department of Medicine Grand Rounds (MGR) presentation is entitled "From Passenger to Driver: How Clonal Hematopoiesis Rewires Cancer Risk," and took place April 8, 2026 on Stanford campus.

Presenter Ross Levine, MD, is a prominent physician-scientist at Weill Cornell Medicine utilizing innovative genomic technologies to uncover disease mechanisms and develop targeted therapies for acute myeloid leukemia and other cancers.

Learn more about the MGR series at: https://medicine.stanford.edu/education/medicine-grand-rounds.html